Nom du produit:FMOC-ALPHA-METHYL-DL-LEUCINE
IUPAC Name:(2S)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-2,4-dimethylpentanoic acid
- CAS：678992-19-3
- Formule moléculaire：C22H25NO4
- Pureté：95%+
- Numéro de catalogue：CM596748
- Poids moléculaire：367.45
| Unité d'emballage |
Stock disponible |
Prix($) |
Quantité |
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:678992-19-3
- Formule moléculaire:C22H25NO4
- Point de fusion:-
- Code SMILES:CC(C)C[C@](C)(NC(=O)OCC1C2=CC=CC=C2C2=C1C=CC=C2)C(O)=O
- Densité:
- Numéro de catalogue:CM596748
- Poids moléculaire:367.45
- Point d'ébullition:
- N° Mdl:MFCD02682477
- Stockage:
Category Infos
- Fluorenes
- Fluorene is a polycyclic aromatic hydrocarbon insoluble in water and soluble in many organic solvents. Fluorenes are one of the most important fluorescent molecules with applications in polymers, electronic devices, sensors, and photochromic materials.
Column Infos
- LX9211
- Diabetes Care, a peer-reviewed journal of the American Diabetes Association publishes the data from Lexicon’s RELIEF-DPN 1 phase 2 study of LX9211. Adaptor-Associated Kinase 1 (AAK1) is linked to clathrin-mediated endocytosis, and plays a critical role in neuropathic pain and various neurological disorders.
Lexicon’s LX9211 is a selective small molecule inhibitor of AAK1, that is developed as a novel non-opioid approach to neuropathic pain. LX9211 is designed to become an efficacious treatment for moderate-to-severe pain due to diabetic peripheral neuropathic pain (DPNP), which is difficult to manage with current approved medications.
LX9211 is in late-stage development, and the patient enrollment of Phase 2b study will be completed by 2024. Its top-line data is expected in Q2 2025. Lexicon received Fast Track Designation from the FDA for LX9211 in DPNP in 2020.
Recherche 
+86 21 5895 0110 
